Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Carlos Perez Ruixo"'
Autor:
Hiroji Uemura, Takefumi Satoh, Hideyasu Tsumura, Gaku Arai, Keiichiro Imanaka, Kazuhiro Shibayama, Koji Fujii, Brendan Rooney, Angela Lopez-Gitlitz, Byron Espina, Carlos Perez-Ruixo, Eric J. Small, Matthew Smith
Publikováno v:
Prostate International, Vol 8, Iss 4, Pp 190-197 (2020)
Background: In the global Phase-3 Selective Prostate Androgen Receptor Targeting with ARN-509 study, apalutamide plus ongoing androgen deprivation therapy (ADT) significantly increased metastasis-free survival (MFS) and improved other clinical outcom
Externí odkaz:
https://doaj.org/article/d97fbd9a51004654a21352bf6702ce26
Autor:
Juan Jose Perez-Ruixo, Eric J. Small, David Olmos, Daniele Ouellet, Margaret K. Yu, Matthew R. Smith, Paul N. Mainwaring, Carlos Perez-Ruixo, Hiroji Uemura, Oliver Ackaert, Caly Chien, Ji Youl Lee
Publikováno v:
Clinical Cancer Research. 26:4460-4467
Purpose: To evaluate the relationship between exposure of apalutamide and its active metabolite, N-desmethyl-apalutamide, and selected clinical efficacy and safety parameters in men with high-risk nonmetastatic castration-resistant prostate cancer. P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba76624b4291c116cd50b095b87ff61d
https://doi.org/10.1158/1078-0432.ccr-20-1041
https://doi.org/10.1158/1078-0432.ccr-20-1041
Autor:
Huybrecht T’jollyn, Oliver Ackaert, Caly Chien, Angela Lopez-Gitlitz, Sharon McCarthy, Carlos Perez Ruixo, Lawrence Karsh, Kim Chi, Simon Chowdhury, Juan-Jose Perez Ruixo, Neeraj Agarwal
Publikováno v:
Cancer chemotherapy and pharmacology. 89(5)
Apalutamide plus androgen-deprivation therapy (ADT) has been approved for treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC) based on data from phase 3 TITAN study. This analysis was conducted to describe pharmacokinet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fcb3dddea28996499f36c2e568fd8480
https://pubmed.ncbi.nlm.nih.gov/35366072
https://pubmed.ncbi.nlm.nih.gov/35366072
Autor:
John Jezorwski, Juan Jose Perez-Ruixo, Herta Crauwels, Carlos Perez-Ruixo, Oliver Ackaert, David McDougall
Publikováno v:
The AAPS Journal. 23
The single-tablet regimen darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg has undergone phase III studies AMBER (NCT02431247) and EMERALD (NCT02269917) in HIV-infected patients. An existing population pharmacoki
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0fe759544a84f9cc1b92aff565f41d3d
https://doi.org/10.1208/s12248-021-00607-8
https://doi.org/10.1208/s12248-021-00607-8
Autor:
Juan Jose Perez-Ruixo, Caly Chien, Oliver Ackaert, Daniele Ouellet, Carlos Perez-Ruixo, Jonás Samuel Pérez-Blanco, Margaret K. Yu
Publikováno v:
Clinical Pharmacokinetics. 59:229-244
Apalutamide is a next-generation androgen receptor inhibitor approved for treatment of subjects with high-risk, non-metastatic, castration-resistant prostate cancer (NM-CRPC). The objective of this study was to characterize the population pharmacokin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d0050ec54b7aa318e18e1e449dc7e3b
https://doi.org/10.1007/s40262-019-00808-7
https://doi.org/10.1007/s40262-019-00808-7
Autor:
Wayne C. Drevets, Carlos Perez-Ruixo, Stefaan Rossenu, Peter Zannikos, Juan Jose Perez-Ruixo, Partha Nandy, Jaskaran Singh
Publikováno v:
Clinical pharmacokinetics. 60(4)
Esketamine nasal spray is approved for treatment-resistant depression. The objective of this study was to characterize the pharmacokinetics of esketamine and noresketamine in healthy subjects and patients with treatment-resistant depression. Esketami
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::905d78d4874075456cc33b3b630e82de
https://pubmed.ncbi.nlm.nih.gov/33128208
https://pubmed.ncbi.nlm.nih.gov/33128208
Autor:
Brendan Rooney, Matthew R. Smith, Byron M. Espina, Gaku Arai, Eric J. Small, Angela Lopez-Gitlitz, Takefumi Satoh, Hiroji Uemura, Carlos Perez-Ruixo, Hideyasu Tsumura, Keiichiro Imanaka, Kazuhiro Shibayama, Koji Fujii
Publikováno v:
Prostate International
Prostate International, Vol 8, Iss 4, Pp 190-197 (2020)
Prostate International, Vol 8, Iss 4, Pp 190-197 (2020)
Background In the global Phase-3 Selective Prostate Androgen Receptor Targeting with ARN-509 study, apalutamide plus ongoing androgen deprivation therapy (ADT) significantly increased metastasis-free survival (MFS) and improved other clinical outcome
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::729cb9a8c5401be1d89e93e144b548bd
https://pubmed.ncbi.nlm.nih.gov/33425798
https://pubmed.ncbi.nlm.nih.gov/33425798
Publikováno v:
The AAPS Journal. 21
Non-adherence to antipsychotic medication is a primary factor in disease relapse in schizophrenic patients. We sought to evaluate if plasma concentrations of the antipsychotic risperidone can be used as a predictor of treatment adherence and to ident
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e30250bb23404dbb7cdadec5f079c987
https://doi.org/10.1208/s12248-019-0299-9
https://doi.org/10.1208/s12248-019-0299-9
Autor:
Sameer Doshi, Carlos Perez Ruixo, Murad Melhem, Juan Jose Perez Ruixo, John David Clements, John P. Gibbs
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology
Optimal dose selection in clinical trials is problematic when efficacious and toxic concentrations are close. A novel quantitative approach follows for optimizing dose titration in clinical trials. A system of pharmacokinetics (PK), pharmacodynamics,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::efea51176602a16fd6b0e1fd76dd34f5
https://pubmed.ncbi.nlm.nih.gov/30246497
https://pubmed.ncbi.nlm.nih.gov/30246497
Autor:
Mario González-Sales, Bernardo Miguel-Lillo, Juan Jose Perez-Ruixo, Carlos Perez-Ruixo, Belén Valenzuela, Carlos Fernandez Teruel, Arturo Soto-Matos
Publikováno v:
Cancer Chemotherapy and Pharmacology. 69:15-24
The aim of this study was to characterize the population pharmacokinetics of PM00104 (Zalypsis(®)) in cancer patients.A total of 135 patients included in four phase I clinical trials who receive intravenous PM00104 at doses ranging from 53 to 5,000
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b0441d3b5ed59bc403ece4dea4f97d45
https://doi.org/10.1007/s00280-011-1644-6
https://doi.org/10.1007/s00280-011-1644-6